How mathematical modeling could contribute to the quantification of metastatic tumor burden under therapy: insights in immunotherapeutic treatment of non-small cell lung cancer

Table 2 Patient-specific clinical parameters

Patient	KE-01	KE-02	KE-03
Sex	F	M	M
Histology	Adenosquamous Carcinoma	Adenocarcinoma	Adenocarcinoma
Molecular Pathology	EGFR-, PD-L1 5, CK7+, TTF1+,	EGFR-, ALK-, KRAS-, BRAF-,	EGFR-, ALK-, KRAS-,
	p63+, Chromogr-, Syn-	PD-L1 50, Ros1-	BRAF- PD-L1 5
TNM Classification	cT4 cN2 cM1b	cT1b pN3 M1a	cT4 cN3 cM0
ECOG-PS	1	0	0
Size of PT at primary diagnosis [ml]	240.74	14.27	71.75

The three patients with NSCLC examined in this study were routinely treated with a prior Cisplatin/Pemetrexed Chemotherapy and/or 1L/2L immunotherapy (Pembrolizumab or Nivolumab), see “Results” section 4 for further details. The molecular pathology features diverse histological testing of tumor markers as follows: EGFR: Epidermal Growth Factor Receptor, PD-L1: Programmed Death Ligand 1, CK7: Cytokeratin 7, TTF1: Thyroid Transcription Factor 1, p63: Tumor Protein 63, Chromogr: Chromogranin A, Syn: Synaptophysin, ALK: EML4-ALK fusion protein, KRAS: Kirsten Rat Sarcoma, BRAF: rapid accelerated fibrosarcoma (B-Type), Ros1: rather often translocated in sarcoma. The sign “+” or “-” indicates a positive respective negative test result for those gene translocations and upregulations. The connection of mentioned markers to the diagnosis of tumor histology is explained in the first section

ISSN: 1742-4682